Downgrading skin climacteric aging by hormone replacement therapy

Expert Review of Dermatology

Volumn 2, Issue 4, 2007, Pages 373-376

  Quatresooz, Pascale ^a   Piérard, Gérald ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; TIBOLONE;

AGING; ALOPECIA; BREAST CANCER; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; EDITORIAL; ENDOMETRIUM HYPERPLASIA; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; PATIENT SELECTION; PRIORITY JOURNAL; SEBUM SECRETION; SKIN BLOOD FLOW; SKIN BRUISING; SKIN EPITHELIUM; VENOUS THROMBOEMBOLISM; WRINKLE; XEROSIS;

EID: 34547877957     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.2.4.373     Document Type: Editorial

References (26)

1. Viscoli CM, Brass LM, Kerman WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen replacement therapy after ischemic stroke. N. Engl. J. Med. 345, 1243-1249 (2001).
2. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/ Progestin Replacement Study follow-up (HERS II). JAMA 288, 49-57 (2002).
3. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291, 1701-1712 (2004).
4. Scarabin PY, Oger E, Plu Bureau G. Differential association of oral and transdermal estrogen replacement therapy with venous thromboembolism risk. Lancet 362, 428-432 (2003).
5. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer 114, 448-454 (2004).
6. Piérard GE. The quandary of climacteric skin ageing. Dermatology 193, 273-274 (1996).
7. Quatresooz P, Piérard-Franchimont C, Gaspard U, Piérard GE. Skin climacteric aging and hormone replacement therapy. J. Cosmet. Dermatol. 5, 3-8 (2006).
8. Raine-Fenning NJ, Brincat M, Muscat-Baron Y. Skin ageing and menopause: implications for treatment. Am. J. Clin. Dermatol. 4, 371-378 (2003).
9. Sauerbronn AV, Fonseca AM, Bagnoli VR, Saldiva PH, Pinotti JA. The effect of systemic hormonal replacement therapy on the skin of postmenopausal women. Int. J. Gynaecol. Obstet. 68, 35-41 (2000).
10. Oikarinen A. Systemic estrogens have no conclusive beneficial effect on human skin connective tissue. Acta Obstet. Gynecol. Scand. 79, 250-254 (2000).
11. Hermanns-Lê T, Uhoda I, Smitz S, Piérard GE. Skin tensile properties revisited during ageing. Where now, where next? J. Cosmet. Dermatol. 3, 35-40 (2004).
12. Castelo-Branco C, Figueras F, Martinez de Osaba MJ, Vanrell JA. Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy. Maturitas 29, 75-86 (1998).
13. Piérard-Franchimont C, Cornil F, Dehavay J, Letot B, Deleixhe-Mauhin F, Piérard GE. Climacteric skin ageing of the face. A prospective longitudinal intent-to-treat trial on the effect of oral hormone replacement therapy. Maturitas 32, 87-93 (1999).
14. Henry F, Quatresooz P, Valverde-Lopez JC, Piérard GE. Blood vessel changes during pregnancy. A review. J. Cosmet. Dermatol. 7, 65-69 (2006).
15. Margolis DJ, Knauss J, Bilker W. Hormone replacement therapy and prevention of pressure ulcers and venous leg ulcers. Lancet 359, 675-677 (2002).
16. Castello-Branco, C, Pons F, Gratacos E, Fortuny A, Vanrell JA, Gonzales-Merlo J. Relationship between skin collagen and bone changes during aging. Maturitas 18, 199-206 (1994).
17. Shah MG, Maibach HI. Estrogen and skin: an overview. Am. J. Clin. Dermatol. 2, 143-150 (2001).
18. Piérard GE, Vanderplaetsen S, Piérard-Franchimont C. Comparative effect of hormone replacement therapy on bone mass density and skin tensile properties. Maturitas 40, 221-227 (2001).
19. Piérard GE, Piérard-Franchimont C, Vanderplaetsen S, Franchimont N, Gaspard U, Malaise M. Relationships between bone mass density and tensile strength of the skin in women. Eur. J. Clin. Invest. 31, 731-735 (2001).
20. Piérard-Franchimont C, Letawe C, Goffin V, Piérard GE. Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas 22, 151-154 (1995).
21. Paquet F, Piérard-Franchimont C, Fumal I, Goffin V, Paye M, Piérard GE. Sensitive skin at menopause; dew point and electrometric properties of the stratum corneum. Maturitas 28, 221-227 (1998).
22. Roux C. Randomised, double-masked, 2 years comparison of tibolone with 17β estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporosis Int. 13, 241-248 (2002).
23. Piérard-Franchimont C, Piérard GE. Post-menopausal aging of the sebaceous follicle. A comparison between women receiving hormone replacement therapy or not. Dermatology 204, 17-22 (2002).
24. Callens A, Vaillant L, Lecomte P, Berson M, Gall Y, Lorette G. Does hormonal skin aging exist? A study of influence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques. Dermatology 193, 189-291 (1996).
25. Guinot C, Malvy D, Ambroisine L et al. Effect of hormonal replacement therapy on skin biophysical properties of menopausal women. Skin Res. Technol. 11, 201-204 (2005).
26. Wines N, Willsteed E. Menopause and the skin. Austral. J. Dermatol. 42, 149-160 (2001).